Key Takeaways:
Canopy Growth Corp. (CGC) shares surged 23 percent Wednesday following reports the U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug.
The stock's performance has drawn a #2 (Buy) rating from Zacks Investment Research, which pointed to a significant year-over-year improvement in earnings estimates. In its upcoming report, analysts expect Canopy Growth to post a loss of six cents per share, a 93.6 percent improvement from the year-ago quarter.
In the latest trading session, Canopy Growth closed at $1.14, with the reclassification news sending shares soaring. Our latest consensus estimate expects revenue to be $53.26 million, a 17.6 percent increase from the same quarter last year. For the full fiscal year, Zacks Consensus Estimates project revenue of $210.58 million, up 8.9 percent from last year.
The potential reclassification represents one of the most significant federal changes to marijuana policy in decades, potentially reshaping the cannabis industry by lowering tax burdens and making it easier for companies to secure banking services and list on major U.S. exchanges.
Despite the bullish news, the stock is down more than 99 percent over the past five years, a period marked by heavy cash burn and shareholder dilution to cover losses. The company has struggled with profitability in the competitive Canadian market while being unable to enter the U.S. market directly.
The reclassification could be a pivotal turning point for Canopy Growth and its peers, including Tilray Brands and Trulieve Cannabis, which also saw their stocks rise on the news. The move would fundamentally improve the operating environment for a sector that has been hampered by federal prohibition.
This policy shift signals a potential lifeline for cannabis companies, validating the improving financial outlook suggested by analyst estimates. Investors will now watch for the official announcement from the DEA, which could come as early as this week.
This article is for informational purposes only and does not constitute investment advice.
